BioSpace News Archive

Inhibikase Therapeutics, Inc. announced that it is advancing its Phase 2a study following review of the study protocol and Phase 1/1b data by the U.S. Food and Drug Administration.

Neurocrine Biosciences, Inc. announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which demonstrated substantial reductions in adrenal androgens and androgen precursors.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced Phase 2b results of avexitide in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic hypoglycemia (HH) after other gastrointestinal surgeries.

Company receives FDA IND clearance for linsitinib and prepares to initiate Phase 2b clinical trial.

Company expands musculoskeletal oncology portfolio with device to treat pediatric bone cancer.

Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies for chronic age-related diseases targeting senescent cells that drive cellular aging, announced the appointments of Judith Campisi, Ph.D., Francesca Grisoni, Ph.D., and Mario Lacouture, M.D., to its Scientific Advisory Board.

D. E. Shaw Research (DESRES) today announced that it has entered into an exclusive global license agreement with Eli Lilly and Company (Lilly) for the clinical development and commercialization of DESRES’s program of Kv1.3-targeted therapeutics for the treatment of various immunological and inflammatory diseases.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company will present data from its hypoimmune platform at the International Society for Stem Cell Research (ISSCR) 2022 Annual Meeting taking place from Wednesday, June 15 through Sunday, June 19 in San Francisco.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company’s participation in the 2022 BIO International Convention on June 13 - 16, 2022, in San Diego, California.

Innovent Biologics, Inc. announced that the China’s National Medical Products Administration has formally accepted the New Drug Application for tafolecimab injection for the treatment of primary hypercholesterolemia and mixed dyslipidemia.